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ABSTRACT
Objective: The reactivity of gynecologic cancer proteins with monoclonal antibody (MAb) directed
against the human immunodeficiency virus I (HIV-I) was tested.
Methods: Cytoplasmic and nuclear proteins, extracted from a broad range ofgynecologic cancers
obtained during standard surgical procedures, were tested in Western blotting with MAb 5023
developed against the amino acid sequences 308-322 of the envelope protein gp120 of HIV-I.
Results: Three cell membrane proteins, Mrl20,000 (p120), Mr41,000 (p41), and Mr24,000 (p24), and
one chromatin protein, Mr24,000 (p24), were detected by MAb 5023 in invasive, poorly differentiated
cervical squamous-cell carcinoma; ovarian serous cystadenocarcinoma; poorly and well-differentiated
endometrial carcinoma; vulvar squamous-cell carcinoma; and malignant mixed mfillerian tumor. The
same antigens were identified in cervical carcinoma cell line SiHa. Neither p120 norp24was recognized
by otherMAbs directed against the variable loop ofgp120. Antigens p120 and p41 were undetectable in
normal ovarian tissue and in biopsy samples ofnormal vaginal and rectal mucosa. Rectosigmoid cancer
as well as colon carcinoma, lung carcinoma, and melanoma cell lines all tested negative.
Conclusions: The identified antigens may represent either the products ofhuman genes (proto-onco-
genes) or, more likely, the products ofan unknown virus specifically expressed in female cancer.
(C) 1994 Wiley-Liss, Inc.
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ancer of the female genital tract accounts for
almost 80,000 cases of invasive cancer each
year in the United States, with the majority of these
being of 3 neoplasms: carcinoma of the cervix,
endometrial carcinoma, and epithelial carcinoma of
the ovary. Ovarian carcinoma and breast carci-
noma together account for one-third of all cancers
occurring in women and are responsible for ap-
proximately one-quarter of cancer-related deaths in
females.
1-3 Inherited forms of ovarian and breast
cancer may frequently
4-6 be associated with the
genetic locus BRCA17 or with mutations in other
genes like p538 or Her2/erbB29 or estrogen recep-
tors.
10 Since most gynecologic cancer patients do
not exhibit any known genetic abnormalities, the
etiology of these cancers remains unclear.
Due to the retroviral origin of several cancers in
other vertebrates,
11 a search for cancer virus in
humans was performed in several laboratories.
12-14
However, except for cervical cancer which is defi-
nitely linked with human papillomavirus infec-
tion,
is, 16 the viral etiology of female malignancies
has never been confirmed.
On the other hand, 50% ofhuman immunodefi-
ciency virus (HIV)-infected women develop cervi-
cal cancer, which has a more virulent course in
HIV-infected than in noninfected women.
17-22 Im-
munodeficiency which follows HIV infection, was
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presented as an explanation for the unusually fast
progression of cervical cancer in these patients,
i)
We report that HIV-cross-reactive antigens are
expressed in several gynecologic cancers and may
represent novel markers of female malignancies.
Since many other cancer-associated antigens are also
expressed in much smaller quantities on normal cell
counterparts, the identification of novel, cancer-
specific targets
23-2s is necessary for effective cancer
diagnosis and immunotherapy.
SUBJECTS AND METHODS
Gynecologic Cancer
Samples of ovarian, cervical, endometrial, vulvar,
and mixed mtillerian tumors were obtained during
standard surgical procedures. The histologic struc-
ture of each cancer was determined by the Depart-
ment of Pathology of the University of Nebraska
Medical Center. Rectosigmoid cancer, a nongyne-
cologic cancer, was obtained from the Department
of Pathology and used as a negative control. Nor-
mal vaginal and rectal mucosa and normal ovarian
tissue were collected during the surgery of gyneco-
logic cancer, and the normal histology of these
samples was assessed by the Department of Pathol-
ogy. A small-bowel nodule was surgically removed
from a patient with Sertoli-Leydig cell tumor of the
ovary.
Cell Lines
The SiHa cervical carcinoma cell line was obtained
from the American Type Tissue Culture Collection
and grown in Eagle’s minimal essential medium/
Leibovitz’s L15 medium (3:4) supplemented with
10% fetal bovine serum.
PBS, and tested by the light microscope. Ovarian
cancer was free of erythrocytes, while cervical, en-
dometrial, and vulvar cancer contained 4-7% of
erythrocytes. The cells were homogenized in 0.3 5
M sucrose/10 mM KCI/1.5 mM MgCli/10 mM
Tris-HCl (pH 7.6)/0.12% Triton X-100/12 mM
2-mercaptoethanol (approximately ml/0.5 cm
3 of
the cancer tissue, with the exception of cervical
cancer, which was ml/0.25 cm) and centrifuged
at 600 g for 10 min. The supernatant was defined as
the cytoplasmic fraction (crude, membrane-contain-
ing). In some experiments, the cytoplasm was cen-
trifuged for another 30 min at 10,000 g to remove
mitochondria and then for h at 100,000 g to
obtain the microsomal (plasma-membrane) frac-
tion. The nuclear pellet was first washed with 0.2
M sucrose/3 mM CaCl2/50 mM Tris-HC1 (pH
7.6) and then with 0.14 M NaC1/10 mM Tris-
HCl (pH 8.3) and centrifuged at 700 g for 10
min. The pellet was swollen in a small amount of
mM Tris-HCl (pH 7.9) and centrifuged through
1.7 M sucrose, 10 mM Tris-HC1 (pH 7), at
160,000 g for 80 min. Chromatin was pelleted at
the bottom of the tube.
Electrophoresis of Proteins
Nuclear, chromatin, cytoplasmic, and membrane
proteins were analyzed by electrophoresis in 7.5-
10% polyacrylamide gel with 0.1% sodium dode-
cyl sulfate (SDS) in buffer containing 250 mM
Tris-HC1 (pH 8.3), 195 mM glycine, and 0.1%
SDS, according to Laemmli et al.
27 Gels were run
at 100 V for 3-4 h. The molecular weights of
proteins were estimated using high-range and low-
range prestained protein markers from Bio-Rad.
Monoclonal Antibodies
Monoclonal antibodies (MAbs) 5023 and 5025
(against HIV-1 gp120 amino acid region 308-
322)2s’26 are from the DuPont Company. Iodina-
tion of MAbs was routinely performed by the IO-
DOGEN method, as described.
2s The specific
activity ofMAb was 10-20 cpm/pg.
Tissue Fractionation
The cancer and normal tissue samples obtained dur-
ing surgery were extensively washed with phos-
phate-buffered saline (PBS) and pressed through a
cell-separating mesh sieve (Sigma). Cells were cen-
trifuged (600 g for 5 min), washed 3 times with
Western Blotting
Blotting of proteins from the polyacrylamide gel to
the polyvinylidene difluoride (PVDF) membrane
was performed in the Tris-glycine (25 mM Tris-
HC1 (pH 8.6), 192 mM glycine buffer, contain-
ing 10% methanol. Transfer onto the PVDF
membrane was performed at 50 V overnight. Mem-
branes were washed with water, followed by Tris-
glycine buffer. Filters were incubated with 1%
bovine serum albumin (BSA) for 16 h at 0C, then
incubated with MAb 5023 or 5025 (2 Ixg/ml),
washed with Tris-glycine buffer, and incubated
with alkaline phosphatase-conjugated goat anti-
mouse IgG for h. After being washed with the
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Tris-glycine buffer, the membranes were incubated
with 0.1% 1-naphthyl-phosphate and Fast Red, in
100 mM Tris-HC1 (pH 9.5), 100 mM NaC1, 5
mM MgC12.
RESULTS
Reactivity of Gynecologic Cancer-Associated
Antigens With MAb Against HIV-I gpl20
MAb 5023 directed against HIV-I gpl20 was
tested in Western blotting for reactivity with cyto-
plasmic, plasma-membrane, nuclear, and chroma-
tin proteins of ovarian, cervical, endometrial, and
vulvar cancer and mixed mtillerian tumor obtained
during surgery. To eliminate a possibility ofMAb
5023 cross-reactivity with cells other than malig-
nant, which are present in the cancer isolated from
the patient, the cervical cancer cell line SiHa was
used in the same set of experiments. Three antigens
were detected by MAb 5023 in the cytoplasmic/
plasma-membrane fraction of all gynecologic can-
cer types: high molecular weight proteins of
mr120,000 (p120), Mr41,000 (p41), and
Mr24,000 (p24)(Fig. 1A-C). The number of
cancer samples that tested positive for particular
antigens are shown in Table 1. All samples tested
positive for p24 and most were also positive for
p 120, p41, or both. Another MAb directed against
HIV-I gpl20, MAb 5025, reacted very weakly
with Mr41,000 antigen (Fig. 1D), but not with
other antigens.
Cervical Cancer
In a model experiment with cervical cancer cell line
SiHa, the 3 antigens p120, p41, and p24 were
detected by MAb 5023 in the cytoplasm and the
antigens p41 and p24 in the chromatin (Fig. 1A,
lanes 5, 6).
MAb 5023 reacted with all cervical cancer sam-
ples obtained from 9 different patients; however,
the expression of particular antigens varied. All
cancer samples were histologically analyzed and de-
scribed as invasive, poorly differentiated squamous-
cell carcinomas. Cervical cancer CI (Fig. 1, lane 1)
and CII (not shown) expressed a well-seen cytoplas-
mic antigen p41 and a much weaker p24, but did
not express p 120. Cervical cancer sample CIII ex-
pressed only MAb 5023-reactive protein, p24
(Fig. 1, lane 2). In cancer CIV, MAb 5023 de-
tected 2 antigens, p 120 and p24, but did not detect
p41 (Fig. A, lane 3). In cancer CV (Fig. A, lane
4) and CVI, CVII, CVIII, and CIX (not shown),
all 3 antigens (p120, p41, and p24) were detected.
Due to the small size of the cervical cancer, separa-
tion of the nucleus from the cytoplasm was not
always possible, and total extracts of cervical cancer
ClV and CV (lanes 3, 4) were analyzed. However,
since p120 is expressed in neither the chromatin of
the SiHa cell line (Fig. 1A, lane 6) nor the chro-
matin of other gynecologic cancers (Fig. 1B,C),
strictly cytoplasmic localization of p120 may be
established. In addition to the 3 major antigens
migrating in the gel with the same mobility as the
antigens expressed by the cell line SiHa (Fig. 1A,
lane 5), a few protein bands of lower molecular
weights (<24,000) were detected in some cervical
cancer samples (Fig. 1A, lanes 1, 4). Whether
these low molecular weight proteins represent deg-
radation products was not established.
Ovarian Cancer
Antigen p120 was detected by MAb 5023 in the
cytoplasm of all tested ovarian cancer samples (Fig.
1B, Oil-lane 3, OIII-lane 4, OIV-lane 6, OV not
shown, OVII-Fig. 3, lane 1), except for cancer
obtained from patient OI (Fig. 1B, lane 1) and
OVI (not shown). Cancer OI was histologically
characterized as poorly differentiated papillary se-
rous adenocarcinoma involving the left fallopian
tube and ovary. Ovarian cancer OVI was histolog-
ically described as mucinous adenocarcinoma. The
other cancers (OIl-V) were described as typical
serous cystadenocarcinomas of the ovary with the
exception of OVII, which was the endometrioid
carcinoma of the ovary.
Antigen p120 was undetectable in the nuclear
fractions (Fig. 1B, lanes 2, 5, 7). The Mrl20,000
band visible in Figure 1B, lane 2, represents impu-
rities attached from the cytoplasm to the nucleus
during cell fractionation. After purification of the
chromatin, the Mrl20,000 band was not visible
(not shown). Antigen p41 was detected as a weak
band in all ovarian cancer samples, but it was de-
tected at a relatively high level in the nucleus of
ovarian cancer OIII.
Antigen p24 was visible in the cytoplasm and in
the nucleus of all ovarian cancer samples. Simi-
larly, as in cervical cancer (Fig. 1A), antigen p24
exhibited a clear association with both cytoplasmic
and nuclear fraction (Fig. B, lanes 1-7). In the
cytoplasm, an antigen ofM "-’20,000 frequently
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TABLE I. Expression of HIV-I cross-reactive
antigens in gynecologic cancer
Cancer type
Antigens detected by
MAb anti-HIV-I gp120
No. of patients
tested/no.
tested positive
Cervical p120 9/7
p41 9/7
p24 9/9
Ovarian p120 7/5
p41 7/7
p24 7/7
Endometrial p120 4/4
p41 4/4
p24 4/4
Mixed millerian p120 3/3
tumor p41 3/3
p24 3/3
Vulvar p 120 I/I
p41 I/I
p24 I/I
aThe antigens were identified by Western blot analysis ofthe cytoplasmic
fraction with MAb anti-Hl-I gp120. Each experiment was repeated 4-7
times with 100% reproducibility of the results.
followed p24 (Fig. 1B, lanes 3, 4, 6). In the nu-
clear fraction, the protein of Mr20,000 was unde-
tectable, but instead a few M < 20,000 bands
were visible. Due to the low molecular weights of
these bands, we cannot exclude the possibility that
these bands represent the products of protein degra-
dation.
Endometrial Cancer
In endometrial cancer EII, which according to the
histologic analysis represented poorly differentiated
adenocarcinoma, all 3 cytoplasmic antigens (p 120,
p41, p24) and p24 in the chromatin (Fig. 1C,
lanes EII-C, N) strongly reacted with MAb 5023.
The reactivity ofMAb 5023 with p120 was stron-
Fig. I. Western blotting of MAb 5023 (A-C) and of the
control MAb 5025 (D) directed against HIV-I gpl20, with
cytoplasmic (C), nuclear (N), total (C+N), or chromatin
(Ch) fractions isolated from particular cancer samples. The
sample marked as pelvic cancer (C) was analyzed prior to the
histologic examination and represents mixed millerian tu-
mor. Proteins were separated in 7.5-12% polyacrylamide
gel. Different migration is due to the different time of elec-
trophoresis and a different gel density. Prestained protein
markers (high and low molecular weight) were used in each
experiment to determine the molecular weights of the anti-
gens. Rectosigmoid cancer in C is shown as a negative con-
trol, i.e., a nongynecologic cancer.
MrxlO-3
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Fig. 2. Western blotting of MAb 5023 with cytosolic (lane
I), microsomal (lane 2), and chromatin (lane 3) fractions of
mixed millerian tumor (PIll), nonmalignant nodule from the
small bowel (lane 4), normal colon mucosa (lanes 5--7), and
vaginal mucosa (lanes 8, 9). C, cytoplasm; Cs, cytosol; P,
microsomal fraction; Ch, chromatin; C + N, extract from
nonfractionated cells.
ger than with other antigens in the same tissue and
also stronger than in any other tested cancer (Fig.
1A-C). In contrast to p120, p24 was much weaker
than in cervical cancer (Fig. 1A), ovarian cancer
(Fig. 1B), mixed mfillerian tumor, or vulvar can-
cer (Fig. 1C). The second endometrial cancer, EI
(Fig. C, EI), which histologically represented
well-differentiated adenocarcinoma, also expressed
all 3 antigens. However, the reaction of p 120 with
MAb 5023 was weaker, and the reaction of p24
was stronger than in EII. Antigen p20 followed
p24. The nucleus contained only p24 (not shown).
Two other patients with advanced endometrial
cancer (not shown) showed the same pattern as pa-
tient EII.
Mixed Millerian Tumor
Three mixed mtillerian tumors were tested. All 3
antigens, p120, p41, and p24 (Fig. 1C, PI), re-
acted in Western blotting with MAb 5023. Other
samples (PII not shown) and PIII (Fig. 2) showed
exactly the same pattern as PI.
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Vulvar Cancer
Vulvar cancer (invasive squamous-cell carcinoma)
showed 3 protein bands (p120, p41, and p24) in
the cytoplasm as well as p41 and p24 (Fig. 1C,
lanes VI-C and VI-N, respectively) in the nucleus.
Cytosolic Localization of Antigen p120
The experiments shown in Figure were done with
the crude, membrane-containing cytoplasmic frac-
tion. In order to determine whether the antigens
recognized by the anti-HIV-I MAb 5023 exhibit
plasma-membrane or cytosolic localization, the cy-
toplasm isolated from the mixed mtillerian tumor
of patient PIII was split into pure cytosol, microso-
mal, and chromatin fractions (see Methods sec-
tion). Electrophoretic analysis followed by West-
ern blotting showed that p120 was localized
selectively in the cytosolic fraction (Fig. 2, lane 1),
while p24 was mainly detected in the microsomal
fraction and in the chromatin (Fig. 2, lanes 2, 3).
Specificity of MAb 5023 Binding to Gynecologic
Cancer Antigens
Cancers other than gynecologic cancer did not react
with MAb 5023. Rectosigmoid cancer, fraction-
ated into cytoplasmic and nuclear fractions, did not
react with MAb 5023 at the Mrl20,000 and
Mr41,000 region. Very weak bands were detected
in the cytoplasm and in the chromatin at the
Mr24,000 region (Fig. 1C, R-SI). MAb 5023
also did not react with a broad range of colorectal
carcinoma, lung carcinoma, and melanoma cell
lines (not shown).
24 A nodule isolated from the
small bowel of the patient with a Sertoli-Leydig cell
tumor of the ovary, which was histologically char-
acterized as fibrous tissue, also tested negative in
Western blotting with MAb 5023 (Fig. 2, lane 4).
Normal colon mucosa obtained from 2 different
patients (Fig. 2, lanes 5-7) and vaginal mucosa
(Fig. 2, lanes 8, 9) also did not react with MAb
5023 except for a weak reaction with the M24,000
protein.
The normal ovarian tissue biopsy from patient
OVII (Fig. 3, lane 2) did not show reactivity with
MAb 5023 except for reactivity with the Mr24,000
protein, although cancer isolated from the same
patient (Fig. 3, lane 1) exhibited a strong reactivity
of p 120 and p41 with MAb 5023.
In general, the HIV-cross-reactive antigens p 120
and p41 were found to be specifically expressed in
Mrxl0-3
OVARIAN
Cancer Tissue
120
25-
2
PATIENT NR O Z3E
Fig. 3. Western blotting of MAb 5023 with the cytoplasmic
fraction from ovarian cancer (lane I) and normal ovarian
tissue (lane 2) from the same patient OVII.
gynecologic cancer but were not expressed in nor-
mal tissues or in other tumors.
DISCUSSION
MAb 5023 developed against amino acid residues
308-322 of the variable V3 loop of the HIV-1
envelope protein gpl20 was found to cross-react
with antigens p120, p41, and p24 in a broad range
of gynecologic cancers, including squamous-cell
carcinoma of the cervix, ovarian serous cystadeno-
carcinoma, endometrial cancer, malignant mixed
mtillerian tumor, and vulvar cancer. Antigen p120
was selectively localized in the cytoplasm, while
p41 and p24 were localized in the cytoplasm and
the nucleus.
In addition to the reactivity with gynecologic
cancer, MAb 5023 exhibits strong binding to breast
carcinoma cell antigens p 160/p80, p45, and p24.
24
Since the molecular weight of p 160 in breast cancer
cells corresponds to the molecular weight of the
precursor for HIV envelope proteins, and the mo-
lecular weight of p 120 in gynecologic cancer corre-
sponds to the molecular weight of the HIV enve-
lope antigen gp 120, an accidental homology ofshort
epitopes is highly unlikely. Since MAb directed
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against I-IIV-I gpl20 is effectively internalized by
breast cancer
24 and cervical cancer cells, which
leads to stimulation of cell proliferation (Rakowicz-
Szulczynska, unpublished data), a growth-factor
receptor-like character of HIV-cross-reactive can-
cer antigens may be anticipated. The fact that HIV-
cross-reactive antigens are expressed in various gy-
necologic cancers of different histologic structures
would support the growth-factor receptor-like char-
acter of these proteins. On the other hand, the
HIV- 1-cross-reactive antigens were undetectable in
colorectal carcinoma, lung carcinoma, and mela-
noma cell lines, which makes a simple growth-
factor receptor-like character of these proteins
highly unlikely. We suggest that an unknown ret-
rovirus with some homology to HIV-1 might be
expressed in gynecologic cancer. Very recently, we
have obtained results with the polymerase chain
reaction (PCR) confirming that long regions with
100% homology to HIV-I are present in gyneco-
logic cancerDNA (Rakowicz-Szulczynska, unpub-
lished data).
HIV-cross-reactive antigens p120 and p41 seem
to be selectively expressed by cancer cells. Normal
ovarian tissue, vaginal mucosa, and colon mucosa
did not express p120 or p41. It is also noteworthy
that rectosigmoid cancer (Fig. 1C), as well as sev-
eral melanoma, colorectal carcinoma, and lung car-
cinoma cell lines tested previously,
24 do not express
HIV-cross-reactive antigens p 120 and p41. Thus,
these antigens are specifically associated with
breast
24 and gynecologic cancer. In contrast to p 120
and p41, p24 was found in some other cancer cell
lines,
24 as well as in normal ovarian tissue and in
noninfected lymphocytes.
25 Protein p24 cannot be
considered a cancer-associated antigen.
MAb 5023 was developed against a short poly-
peptide (RIQRGPGRAFVTIGK), corresponding
to the amino acids 308-322 of I-IIV-1 gpl20, but
this MAb binds to the much shorter amino acid
region GRAF.
26 It is likely that this core epitope is
expressed in gynecologic cancer and breast cancer
antigens. Another MAb, MAb 5025, which was
developed against the same synthetic peptide but
recognizes the sequences RAF, did not bind to
gp 120 and p24, but reacted weakly with p41 (Fig.
1D). It is noteworthy that a fraction of human
antibodies isolated from HIV-infected people also
recognized in Western blotting breast cancer
24 and
gynecologic cancer (unpublished data) antigens.
The results suggest that HIV-infected patients pro-
duce antibodies that cross-react with cancer. The
biological function and diagnostic value, as well as
the genetic origin, of the HIV-cross-reactive cancer
antigens remain to be further investigated.
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